SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese owner and operator of aesthetic medical clinics, has implemented strategies throughout 2025 that have strengthened its market position and set the stage for expansion in the coming year. The company focused on making aesthetic medicine more accessible while differentiating itself through advanced treatments and competitive pricing, resulting in increased clinic numbers, higher customer loyalty, and improved financial metrics. As of September 30, 2025, SBC Medical operates 258 franchise locations, representing a 15% year-over-year increase. The company's revised pricing strategy contributed to a 5% sequential increase in average revenue per customer during the third quarter, reaching $298 per visit. This optimization, combined with efforts to attract higher-revenue customers through a multi-brand approach, has driven financial improvement. The company reported a significant enhancement in net profit during the third quarter as it returned to a more typical cost structure following its initial public offering.
Beyond domestic growth, SBC Medical has pursued international expansion, entering markets in Singapore and Thailand while announcing its first expansion into the United States for early 2026. In Singapore, the company is expanding its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., which operates multiple brands in the medical aesthetics industry. In Thailand, SBC has entered an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics and is preparing to open a new dermatology-focused clinic in Bangkok with SBC's management support. The company has specifically targeted Chinese consumers who travel to Japan for cosmetic procedures, drawn by the country's reputation for advanced techniques and qualified medical staff. To accommodate this demographic, SBC has increased its Chinese-speaking customer service representatives and interpreters, disseminated information on Chinese social media platforms, developed a dedicated app, and held events in Shanghai to attract new clients.
Strategic acquisitions have further bolstered SBC Medical's capabilities. The company acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions specializing in consulting, training, and human resources solutions. Additionally, SBC acquired a related subsidiary, Waqoo, to accelerate research and development and integrate technologies in clinical areas such as androgenetic alopecia and orthopedics. The companies will jointly develop and promote skincare products. On the corporate front, SBC Medical was added to the Russell 3000 Index, which includes approximately $18.1 trillion in assets benchmarked against the indexes globally. According to the company, this inclusion increases visibility and opens access to a broader base of investors, particularly those who invest in index funds and exchange-traded funds that track Russell indexes. The company also announced a stock buyback program of up to $5 million, citing confidence in its growth plan and belief that its stock price undervalued its business performance and market position.
The global cosmetic surgery and procedure market was valued at $122.08 billion in 2022 and is projected to grow at a compound annual growth rate of 14.7% from 2023 to 2030. SBC Medical's expansion comes as the aesthetics and cosmetic medical market in Japan experiences increased demand from affluent Chinese and other Asian consumers seeking advanced treatments. With a network of over 500 licensed doctors performing regenerative therapies throughout Japan and a repeat customer rate of 72% as of the third quarter, the company has established infrastructure to support its growth objectives. The company's strategic moves throughout 2025 position it to capitalize on this growing market while leveraging its strengthened financial position and expanded operational capabilities.
